On September 30, BIOCYTOGEN-B rose 5.49% in regular trading, reaching HK$68.25 per share, with turnover of approximately HK$48.96 million. The gain came as the broader biotechnology sector saw widespread strength, with CRO/CXO names leading the advance.
On the sector front, the CXO industry has entered a confirmed upswing cycle, with H1 domestic CXO sector revenue and net profit growing 24.5% and 52.7% year-over-year respectively, approaching the prior cycle peak. Order backlogs and new signings have broadly recovered, and leading companies have raised full-year guidance. AI-driven drug discovery is also expected to reshape biopharma R&D and further benefit the sector.
BIOCYTOGEN-B itself reported robust H1 results, with revenue of RMB 941 million, up 51.6% year-over-year, and adjusted net profit of RMB 241 million, surging 402.3%. The company maintained a gross margin of 79.3% and has achieved profitability for five consecutive quarters. Additionally, the company recently signed a nanobody licensing agreement with Qilu Pharmaceutical to support neurology drug development.
Within the Biotechnology sector, CANSINOBIO rose 16.91%, INNOVENT BIO rose 2.45%, BEONE MEDICINES rose 2.75%, 3SBIO rose 1.32%, and AKESO rose 1.13%.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments